# A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

> **NCT01759394** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Avatrombopag maleate 40 mg

## Key facts

- **NCT ID:** NCT01759394
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01759394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01759394, "A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01759394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*